HIV protease inhibitors

US9079834B2 · kind B2 · utility

Assignee

• Merck Canada Inc. · CA

Inventors

• Michael Boyd · Winchester, US
• Carmela Molinaro · Colonia, US
• Amelie Roy · Saint-Lazare, CA
• Vouy Linh Truong · ᐙᔂᓂᐲ Waswanipi, CA

Key dates

• Filing date: Oct 27, 2011
• Grant date: Jul 14, 2015
• Expiry date: Mar 23, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/12
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Compounds of Formula I are disclosed wherein R1, R2, R3A, R3B, R4A, R4B, R5A, R5B, R6A, R6B, R7, R8 and R9 are defined herein. The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.